Discovery of novel benzenesulfonamides incorporating 1,2,3-triazole scaffold as carbonic anhydrase I, II, IX, and XII inhibitors

ArticleAçık Erişim

Özet

Sulfonamides are among the most promising potential inhibitors for carbonic anhydrases (CAs), which are pharmaceutically relevant targets for treating several disease conditions. Herein, a series of benzenesulfonamides bearing 1,2,3-triazole moiety as inhibitors of human (h) α-CAs (hCAs) were designed using the tail approach. The design method combines a benzenesulfonamide moiety with a tail of oxime and a zinc-binding group on a 1,2,3-triazole scaffold. Among the synthesized derivatives, the naphthyl (6m, KI of 68.6 nM, SI of 10.3), and methyl (6a, KI of 56.3 nM, SI of 11.7) derivatives (over hCA IX) and propyl (6c, KI of 95.6 nM, SI of 2.7), and pentyl (6d, KI of 51.1 nM, SI of 6.6) derivatives (over hCA XII) displayed a noticeable selectivity for isoforms hCA I and II, respectively. Meanwhile, derivative 6e displayed a potent inhibitory effect versus the cytosolic isoform hCA I (KI of 47.8 nM) and tumor-associated isoforms hCA IX and XII (KIs of 195.9 and 116.9 nM, respectively) compared with the reference drug acetazolamide (AAZ, KIs of 451.8, 437.2, and 338.9 nM, respectively). Derivative 6b showed higher potency (KI of 33.2 nM) than AAZ (KI of 327.3 nM) towards another cytosolic isoform hCA II. Nevertheless, substituting the lipophilic large naphthyl tail to the 1,2,3-triazole linked benzenesulfonamides (6a-n) raised inhibitory effect versus hCA I and XII and selectivity towards hCA I and II isoforms over hCA IX. Evaluation of the cytotoxic potential of the synthesized derivatives was conducted in L929, MCF-7, and Hep-3B cell lines. Several compounds in the series demonstrated significant antiproliferative activity and minimal cytotoxicity. In the molecular docking study, the sulfonamide moiety interacted with the zinc-ion and neatly fit into the hCAs active sites. The extension of the tail was found to participate in diverse hydrophilic and hydrophobic interactions with adjacent amino acids, ultimately influencing the effectiveness and specificity of the derivatives. © 2023 Elsevier B.V.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/12133Resmi atıflarda kullanılan kalıcı adres
Tam Kayıt
AlanDeğerDil
dc.contributor.authorBuza, Aida
dc.contributor.authorTürkeş, Cüneyt
dc.contributor.authorArslan, Mustafa
dc.contributor.authorDemir, Yeliz
dc.contributor.authorDincer, Busra
dc.contributor.authorNixha, Arleta Rifati
dc.contributor.authorBeydemir, Sükrü
dc.date.accessioned2026-10-18T20:27:04.650601103Z
dc.date.available2026-10-18T20:27:04.650601103Z
dc.date.issued2023
dc.description.abstractSulfonamides are among the most promising potential inhibitors for carbonic anhydrases (CAs), which are pharmaceutically relevant targets for treating several disease conditions. Herein, a series of benzenesulfonamides bearing 1,2,3-triazole moiety as inhibitors of human (h) α-CAs (hCAs) were designed using the tail approach. The design method combines a benzenesulfonamide moiety with a tail of oxime and a zinc-binding group on a 1,2,3-triazole scaffold. Among the synthesized derivatives, the naphthyl (6m, KI of 68.6 nM, SI of 10.3), and methyl (6a, KI of 56.3 nM, SI of 11.7) derivatives (over hCA IX) and propyl (6c, KI of 95.6 nM, SI of 2.7), and pentyl (6d, KI of 51.1 nM, SI of 6.6) derivatives (over hCA XII) displayed a noticeable selectivity for isoforms hCA I and II, respectively. Meanwhile, derivative 6e displayed a potent inhibitory effect versus the cytosolic isoform hCA I (KI of 47.8 nM) and tumor-associated isoforms hCA IX and XII (KIs of 195.9 and 116.9 nM, respectively) compared with the reference drug acetazolamide (AAZ, KIs of 451.8, 437.2, and 338.9 nM, respectively). Derivative 6b showed higher potency (KI of 33.2 nM) than AAZ (KI of 327.3 nM) towards another cytosolic isoform hCA II. Nevertheless, substituting the lipophilic large naphthyl tail to the 1,2,3-triazole linked benzenesulfonamides (6a-n) raised inhibitory effect versus hCA I and XII and selectivity towards hCA I and II isoforms over hCA IX. Evaluation of the cytotoxic potential of the synthesized derivatives was conducted in L929, MCF-7, and Hep-3B cell lines. Several compounds in the series demonstrated significant antiproliferative activity and minimal cytotoxicity. In the molecular docking study, the sulfonamide moiety interacted with the zinc-ion and neatly fit into the hCAs active sites. The extension of the tail was found to participate in diverse hydrophilic and hydrophobic interactions with adjacent amino acids, ultimately influencing the effectiveness and specificity of the derivatives. © 2023 Elsevier B.V.
dc.description.sponsorshipThis work was supported by the Research Fund of Sakarya University (grant number 2020-9-32-85 ), the Research Fund of Erzincan Binali Yıldırım University (grant number TSA-2020-729 ), and the Research Fund of Anadolu University (grant number 2102S003 ).
dc.identifier.doi10.1016/j.ijbiomac.2023.124232
dc.identifier.eissn1879-0003
dc.identifier.issn0141-8130
dc.identifier.pmid37001773
dc.identifier.scopus2-s2.0-85151430516
dc.identifier.startpage124232
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/12133
dc.identifier.volume239
dc.identifier.wosWOS:000970836600001
dc.language.isoen
dc.publisherElsevier B.V.
dc.relation.ispartofInternational Journal of Biological Macromolecules
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBenzenesulfonamide
dc.subjectCarbonic anhydrase
dc.subjectCytotoxicity
dc.subjectIn silico study
dc.subjectSelective inhibitor
dc.subjectAmines
dc.subjectCarbonic Anhydrase I
dc.subjectCarbonic Anhydrase Inhibitors
dc.subjectCarbonic Anhydrase IX
dc.subjectCarbonic Anhydrases
dc.subjectHumans
dc.subjectMolecular Docking Simulation
dc.subjectMolecular Structure
dc.subjectProtein Isoforms
dc.subjectStructure-Activity Relationship
dc.subjectSulfonamides
dc.subjectTriazoles
dc.subject1,2,3 triazole derivative
dc.subject2 [({1 [5 methyl 1 (4 sulfamoylphenyl) 1H 1,2,3 triazol 4 yl] ethylidene}amino)oxy]acetamide
dc.subject4 (4 1 [(heptyloxy)imino]ethyl} 5 methyl 1H 1,2,3 triazol 1 yl)benzenesulfonamide
dc.subject4 (4 {1 [(Allyloxy)imino]ethyl} 5 methyl 1H 1,2,3 triazol 1 yl) benzenesulfonamide
dc.subject4 (4 {1 [(anthracen 9 ylmethoxy)imino]ethyl} 5 methyl 1H 1,2,3 triazol 1 yl)benzenesulfonamide
dc.subject4 (4 {1 [(but 3 en 1 yloxy)imino]ethyl} 5 methyl 1H 1,2,3 triazol 1 yl)benzenesulfonamide
dc.subject4 (5 methyl 4 {1 [(naphthalen 1 ylmethoxy)imino]ethyl} 1H 1,2,3 triazol 1 yl)benzenesulfonamide
dc.subject4 (5 methyl 4 {1 [(octyloxy)imino]ethyl} 1H 1,2,3 triazol 1 yl) benzenesulfonamide
dc.subject4 (5 methyl 4 {1 [(pentyloxy)imino]ethyl} 1H 1,2,3 triazol 1 yl)benzenesulfonamide
dc.subject4 (5 methyl 4 {1 [(prop 2 yn 1 yloxy)imino]ethyl} 1H 1,2,3 triazol 1 yl)benzenesulfonamide
dc.subject4 {4 [1 (methoxyimino)ethyl] 5 methyl 1H 1,2,3 triazol 1 yl} benzenesulfonamide
dc.subject4 {5 methyl 4 [1 (propoxyimino)ethyl] 1H 1,2,3 triazol 1 yl} benzenesulfonamide
dc.subject4{4 [1 (ethoxyimino)ethyl] 5 methyl 1H 1,2,3 triazol 1 yl}benzenesulfonamide
dc.titleDiscovery of novel benzenesulfonamides incorporating 1,2,3-triazole scaffold as carbonic anhydrase I, II, IX, and XII inhibitors
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus83
rdl.citation.wos78
rdl.departmentDepartment of Biochemistry, Faculty of Pharmacy, Erzincan Binali Yıldırım University, 24002 Erzincan, Turkey. Electronic address: cuneyt.turkes@erzincan.edu.tr. | Department of Pharmacology, Faculty of Pharmacy, Erzincan Binali Yıldırım University, 24002 Erzincan, Turkey.
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)